The goal of this observational study is to evaluate how persistently patients with high-risk early breast cancer take abemaciclib 6 months after therapy start. To this end, researchers will perform a retrospective analysis of therapy data.
Femal patients age 18 or older at time of informed consent
Confirmed diagnosis of HR+/HER2- early breast cancer (no distant metastasis)
Prescribed abemaciclib therapy according to the Summary of Product Characteristics (SmPC)
Abemaciclib therapy occured between January 1st, 2023 and June 30th, 2025
Locally advanced or metastatic breast cancer
Male patients
Patients with contraindication(s) for abemaciclib therapy according to SmPC
Institut fuer Frauengesundheit
Lead sponsor
Lilly Deutschland GmbH Germany
Collaborator
AGO-B Breast Study Group
Collaborator